President and CEO, The Angeles Clinic and Research Institute; Professor of Clinical Medicine, Keck School of Medicine, USC
Oncology
Dr. Lawrence Piro, MD
|
|
Give Review
Dr. Lawrence Piro is an expert in the field of Oncology. He attended Washington University School of Medicine in St. Louis. He received 2 awards: "Regional Top Doctor" and "Super Doctor". Doctor Lawrence Piro, MD is a published MD. He has 61 publications published. The most current publication "Long-term follow-up of patients with hairy cell leukemia after cladribine treatment." Lawrence Piro, MD is registered with Medicare and accepts Medicare payments.
Publications
- Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic Melanoma.
- Apoptosis, Bcl-2 antisense, and Cancer therapy.
- 2-Chlorodeoxyadenosine: drug development priorities.
- 2-Chlorodeoxyadenosine treatment of lymphoid malignancies.
- Related cord blood banking for haematopoietic stem Cell transplantation.
- Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic Leukemias, and reactive lymph nodes.
- Autoantibodies to platelet glycoproteins in patients with Disease-related immune thrombocytopenia.
- Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.
- Managed oncology care: the Disease management model.
- 2-Chlorodeoxyadenosine: treatment of hairy cell Leukemia, chronic lymphocytic Leukemia, and lymphocytic lymphoma.
- Loxoribine induces chronic lymphocytic Leukemia B cells to traverse the cell cycle.
- Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell Leukemia and chronic lymphocytic Leukemia.
- Purine metabolism of lymphocytes. Targets for chemotherapy drug development.
- Acute myelogenous leukemia presenting with bulky lymphadenopathy. Case report and literature review.
- Diagnostic application of two-color flow cytometry in 161 cases of hairy cell Leukemia.
- Hairy cell Leukemia: new understanding of biology and treatment.
- Treatment of hairy cell Leukemia.
- New perspectives on the approach to chronic lymphocytic Leukemia.
- Reduced charges and costs associated with outpatient autologous stem Cell transplantation.
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.
- 2-Chlorodeoxyadenosine to treat refractory histiocytosis X.
- 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic Leukemia.
- Cladribine in the treatment of low-grade non-Hodgkin's Lymphoma.
- Lasting remissions in hairy-cell Leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
- 2-Chlorodeoxyadenosine chemotherapy triggers programmed Cell death in normal and malignant lymphocytes.
- Outpatient high-dose chemotherapy with autologous stem-Cell rescue for hematologic and nonhematologic malignancies.
- 2-Chlorodeoxyadenosine treatment of Lymphoma.
- 2-Chlorodeoxyadenosine therapy in chronic lymphocytic Leukemia.
- The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell Leukemia.
- Newer purine analogues for the treatment of hairy-cell Leukemia.
- The newer purine Analogs. Significant therapeutic advance in the management of lymphoid malignancies.
- The optimal management of hairy Cell leukaemia.
- Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
- 2-Chlorodeoxyadenosine in the treatment of hairy cell Leukemia.
- 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
- 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
- 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-Cell histiocytosis.
- 2-Chlorodeoxyadenosine: a newer purine Analog active in the treatment of indolent lymphoid malignancies.
- 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative Disorders.
- Major activity of cladribine in patients with de novo B-cell prolymphocytic Leukemia.
- Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell Leukemia.
- Complete remissions in hairy cell Leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
- 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell Lymphoma.
- 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic Leukemia.
- 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic Leukemia resistant to fludarabine.
- Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
- Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's Lymphoma.
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin''s Lymphoma.
- 2-Chlorodeoxyadenosine treatment of low-grade Lymphomas.
- 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's Lymphoma.
- 2-Chlorodeoxyadenosine in the treatment of hairy cell Leukemia and chronic lymphocytic Leukemia.
- Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.
- 2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous Leukemia.
- Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous Leukemia after 2-chlorodeoxyadenosine.
- Long-term follow-up of patients with hairy cell Leukemia after cladribine treatment.
- A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic Leukemia: results from CALGB Study 9211.
- Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
- Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione Analog prodrug in patients wit...
- A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's Lymphoma.
- Maintenance biotherapy for metastatic Melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to ind...
Schools
Washington Univ Sch Of Med
Barnes HospWash University
Scripps Clin Rsch Fdn
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
Scripps Clinic -
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1124131446 | |
| NPPES Provider LastName | PIRO | |
| NPPES Provider FirstName | LAWRENCE | |
| NPPES Provider ZIPCode | 904042102 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 472.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 21.0 | |
| Percent Opioid Claims | 4.45 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124131446 |
| Last Name Of The Provider | PIRO |
| First Name Of The Provider | LAWRENCE |
| View All |
Similar Doctors
|
Dr. Sant P. Chawla, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter D. Boasberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omid Hamid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marilou Terpenning, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara A. Hurvitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silvana Martino, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sean A. Fischer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel R. Hecht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saeed W. Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamalesh K. Sankhala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee S. Rosen, MD
This Doctor is OpenDoctor Recommended.
|